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Presentation Objectives 
Review the impact of adjunctive midodrine utilization to 
facilitate weaning intravenous (IV) vasopressors in a 
community hospital 
Background
• IV vasopressors are utilized as mainstay therapy for shock in ICU
• Adverse effects: 
– Tachycardia
– Local tissue necrosis
– Gangrene if extravasation occurs
– Bradycardia
– Dysrhythmia 
• Midodrine is an oral alpha-1 adrenergic agonist used as 
adjunctive therapy to wean off IV vasopressors 
– Decreases in ICU LOS and IV vasopressor rate
VanValkinburgh D, Hashmi MF. Inotropes And Vasopressors. [Updated 2019 Oct 24]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020 Jan.  
Supporting Literature
Study Objective Study Design Results 
2013 –
Levine 




therapy to wean 
vasopressors 
• Prospective, observational study 
• Starting: 10 mg TID; 
Max: 40 mg TID
• 20 patients included; 14 weaned 
in 24 hrs
Decreased vasopressor rate after initiating 
midodrine: -0.62 ± 1.40 mcg/min/hr
compared to -2.20 ± 2.45 mcg/min/hr












• Retrospective, single-center, 
observational study 
• 140 patients: vasopressor alone
• 135 patients: vasopressor + 
midodrine
• Starting dose: 10 mg TID;       
Max: 20 mg TID
• Decreased vasopressor duration: 8 days 
(vasopressor only) vs. 2.9 days 
(vasopressor + midodrine) (p<0.001)
• Decreased ICU LOS: 9.4 days (vasopressor 












• Single-center retrospective study
• 1,010 patients included 
• ICU discharge: 67% (672/1,010) 
• Hospital discharge: 34% (311/1,010)
• 50% also prescribed antihypertensives 
• Shorter ICU LOS (7.5 ± 8.9 vs 10.6 ± 13.4 
days) and reduced risk of in-hospital 
mortality (HR, 0.47 [95% CI, 0.32-0.70];    
p < 0.001)
Research Purpose
To assess how adjunctive midodrine is being 
utilized in our institution to wean off vasopressors
To determine whether patients are being 
transitioned off midodirne when it is no longer 
warranted
Research Setting
• Baptist Hospital of Miami 
– Non-profit community hospital 
– 728-bed


















• Adults 18 years of age and older
• ICU admission
• Midodrine prescribed during admission in 
conjunction with IV vasopressor
Exclusion




• Time to vasopressor discontinuation after midodrine initiation
• Percentage of patients transitioned off of midodrine at ICU and hospital 
discharge
Secondary
• Time from midodrine initiation to ICU discharge determination 
• ICU LOS
• Time on vasopressor prior to initiation of midodrine
• Pharmacy interventions in phase II




Dialysis status and 
urine output
APACHE IV score Type of shock
Vasopressor starting 
rate, rate at 
midodrine initiation 
(mcg/kg/hr)
Average rate of 











Initial and maximum 
midodrine 
dose/frequency
Average daily dose 













midodrine (HR, BP, 
both)
Midodrine 
continued post ICU 
or post hospital 
discharge
Type of pharmacy 
intervention
APACHE: acute physiology and chronic health evaluation 











• Midodrine and vasopressor 
not used concomitantly 
• Midodrine x 1














• 13 patients: 
• No vasopressors 
• Midodrine was a home medication
• Midodrine and vasopressor not used 
concomitantly 
• Midodrine x 1
• 7 patients: 
• Continuation of vasopressor and 
midodrine past study deadline
Baseline Characteristics
Characteristics Phase I (N=15) Phase II (N=24) p-value
Age, years (mean, SD) 69.3 ± 16.3 67.6 ± 15.2 p = 0.751
Gender – male, n (%) 12 (80) 15 (63) p = 0.305
APACHE IV Score (mean, SD) 61.9 ± 18.1 43.4 ± 15.2 p = 0.002











Dialysis, n (%) 7 (47) 8 (33) p = 0.505
Hydrocortisone utilization, n (%) 6 (40) 5 (21) p = 0.277
Mechanical ventilation, n (%) 12 (80) 22 (92) p = 0.354
Baseline Characteristics
Vasopressor Information Phase I (N=15) Phase II (N=24) p-value

















Midodrine initial dose, n (%)
5 mg TID






Vasopressor rate in ICU*
(mcg/kg/min) (mean, SD) 9.6 ± 8.1 5.3 ± 3.4 p = 0.025
Vasopressor rate at midodrine 
initiation* (mcg/kg/min) (mean, SD)









• Time to vasopressor discontinuation after midodrine initiation
Phase I (N=15) Phase II (N=24) p-value 
Days (mean, SD) 3 ± 5.2 4 ± 2.8 p = 0.832
• Percentage of patients transitioned off of midodrine
Phase I (N=15) Phase II (N=24) p-value
ICU Discharge, n (%) 6 (40) 19 (79) p = 0.019
Hospital Discharge 9 (60) 22 (92) p = 0.037
Results: Primary Outcome










Home with hospice (2)
Transferred to other 
hospital (2)
Transferred to long-













Variable Phase I (N=15) Phase II (N=24) p-value
Time from midodrine initiation to ICU 
discharge, days (mean, SD)
5 ± 6.7 12 ± 6.1 p = 0.002
ICU LOS, days (mean, SD) 12 ± 8.8 23 ± 11.9 p = 0.006
Time on vasopressor prior to initiation 
of midodrine, days (mean, SD) 
5 ± 6.1 4 ± 2.8 p = 0.587
Midodrine duration, days (mean, SD) 12 ± 8.8 9 ± 8.3 p = 0.267










• Vasopressors were discontinued sooner in phase I (3 days) vs. 
phase II (4 days) after midodrine initiation
– Average vasopressor duration was 8 days in both phases
• Patients in phase I were on vasopressors longer prior to 
midodrine initiation
– Midodrine continued longer in phase I (12 days) vs. phase II (9 days) 
• ICU LOS was shorter in phase I (12 days) vs. phase II (23 days) 
– Causes unrelated to vasopressor utilization 
– Mortality rate was higher in phase I (75%) vs. phase II (45%)
• Pharmacist involvement optimized midodrine therapy
Study Limitations
• Critically ill patients were included in phase I based on 
ICD-10 codes, which may have limited sample size
• Phase I was retrospective and pharmacist interventions 
were not calculated  
• Limited sample size in phase II
• Phase II was conducted during COVID-19 pandemic
Conclusion 
Midodrine was initiated later in phase I and continued for 
longer compared to phase II 
Due to pharmacist interventions in phase II, inappropriate 
use of midodrine was reduced at ICU/hospital discharge 
Future studies are necessary to solidify this correlation in 
our institution 
Assessment Question
Which of the following is the role of midodrine in 
weaning off vasopressors? 
A. Decrease blood pressure to maintain ACC/AHA 
blood pressure goal while in the ICU
B. Increase IV vasopressor rate to facilitate weaning
C. Increase adherence rates of anti-hypertensive 
medications once discharged
D. Decrease IV vasopressor rate, complications and 
ICU length of stay
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